Bellus Health (NASDAQ: BLU)
Some price data may be temporarily unavailable.
Bellus Health Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Bellus Health Company Info
BELLUS Health, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of cough hypersensitivity and other hypersensitization disorders. Its product BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus, or chronic itch. The company was founded on June 17, 1993 and is headquartered in Laval, Canada.
News & Analysis
Why Shares of Bellus Health Skyrocketed This Week
The company has received a buyout offer from GSK.
Why BELLUS Health Stock Is Rocketing Higher Today
A $2 billion buyout agreement with GSK is lighting a fire under the biotech's stock today.
Why BELLUS Health Stock Fell Today
Issuing new shares will leave it with plenty of money in the bank.
Here's Why Bellus Health Is Jumping Higher Today
A phase 2 trial with the company's chronic-cough candidate hit its primary endpoint.
Why Bellus Health Stock Tanked 69.2% Today
The company's lead drug has failed a phase 2 trial.
Valuation
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.